Laboratory Products
FDA sanctions advanced prostate cancer therapy
Apr 30 2010
Provenge (sipuleucel-T) is a method that uses the patient's own bodily defences to tackle the disease and it has been sanctioned for cases where tumours are resistant to normal curative measures and have spread around the body.
It works by obtaining immune cells from the blood, which are then exposed to prostate cancer proteins before being reinserted into the individual.
Laboratory scientists found subjects treated in this manner had a median survival rate of 25.8 months, compared with 21.7 months for the control group.
Dr Karen Midthun of the FDA said: "The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available."
Earlier this month, the organisation approved new Pancreaze Delayed-Release Capsules for boosting food digestion in patients who have suffered illnesses such as pancreatic cancer.
Digital Edition
Lab Asia 31.4 August 2024
August 2024
Chromatography Articles - HPLC gradient validation using non-invasive flowmeters Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers Labo...
View all digital editions
Events
Sep 04 2024 Chiba, Tokyo, Japan
Sep 04 2024 University of Warwick, Coventry, UK
Sep 11 2024 Bangkok, Thailand
Sep 11 2024 Singapore
Sep 11 2024 Bangkok, Thailand